Amedeo's Top 20

Amedeo Smart

Independent Medical Education

25 April 2022

Multidisciplinary Journal Club

  1. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al.
    Endometrial cancer.
    Lancet 2022;399:1412-1428.

  1. Gaebler C, Nogueira L, Stoffel E, Oliveira TY, et al.
    Prolonged viral suppression with anti-HIV-1 antibody therapy.
    Nature 2022.

  2. Forde PM, Spicer J, Lu S, Provencio M, et al.
    Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    N Engl J Med 2022.

  3. Dhana K, Franco OH, Ritz EM, Ford CN, et al.
    Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study.
    BMJ 2022;377:e068390.

  4. Schrijver LH, Mooij TM, Pijpe A, Sonke GS, et al.
    Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    J Natl Cancer Inst 2022;114:540-552.

  1. Vitkova M, Diouf I, Malpas C, Horakova D, et al.
    Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
    Neurology 2022.

  2. Korde LA, Somerfield MR, Hershman DL.
    Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol 2022.

  3. Al-Wahsh H, Lam NN, Quinn RR, Ronksley PE, et al.
    Calculated versus measured albumin-creatinine ratio to predict kidney failure and death in people with chronic kidney disease.
    Kidney Int 2022.

  4. Kanjee Z, Achebe MO, Smith WR, Burns RB, et al.
    How Would You Treat This Patient With Acute and Chronic Pain From Sickle Cell Disease? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med 2022.

  5. Bebo B, Cintina I, LaRocca N, Ritter L, et al.
    Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology 2022.

  1. Casulo C, Dixon JG, Le-Rademacher J, Hoster E, et al.
    Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Blood 2022;139:1684-1693.

  2. Nitz UA, Gluz O, Kummel S, Christgen M, et al.
    Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
    J Clin Oncol 2022.

  3. Willison AG, Ruck T, Lenz G, Hartung HP, et al.
    The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol 2022.

  4. Sible IJ, Nation DA.
    Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults.
    Neurology 2022.

  5. Clayton B, Muneeb F, Hughes MCB, Grant ME, et al.
    Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: a multi-centre study.
    Int J Cancer 2022.

  1. Tideman P, Stomrud E, Leuzy A, Mattsson-Carlgren N, et al.
    Association of beta-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
    Neurology 2022;98:e1525-e1533.

  2. Barroso LF, Stier EA, Hillman R, Palefsky J, et al.
    Anal Cancer Screening and Prevention: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Guidelines.
    Clin Infect Dis 2022;74:S179-S192.

  3. Weiser R, Polychronopoulou E, Hatch SS, Haque W, et al.
    Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
    Cancer 2022;128:1738-1747.

  4. Bizzarri N, Marchetti C, Conte C, Loverro M, et al.
    The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol 2022.

  5. Nitz U, Gluz O, Graeser M, Christgen M, et al.
    De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label%
    Lancet Oncol 2022.


more..

Privacy Policy